Electroretinogram: a new human biomarker for smoking cessation treatment

视网膜电图：戒烟治疗的新人类生物标志物

• 批准号: 9386293
• 负责人: Sean Xiao Luo
• 金额: $ 19.98万
• 依托单位: NEW YORK STATE PSYCHIATRIC INSTITUTE DBA RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC
• 依托单位国家: 美国
• 财政年份: 2017
• 资助国家: 美国
• 起止时间: 2017-07-01 至 2022-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9386293
• 关键词: Abstinence; Address; Alcohol or Other Drugs use; Animal Experiments; Area; Attention deficit hyperactivity disorder; Behavior Therapy; Biological Markers; Brain; Clinical; Clinical Research; Clinical Trials; Cocaine Users; Collaborations; Cone; Corpus striatum structure; Data; Data Analytics; Development; Diagnosis; Disease; Dopamine; Dose; Early treatment; Electroretinography; Exhibits; Funding; Future; Genetic; Gold; Grant; Human; Incentives; Individual; Knowledge; Light; Maintenance; Measures; Medicine; Mental disorders; Mentored Patient-Oriented Research Career Development Award; Mentors; Methylphenidate; Neurotransmitters; Nicotine Dependence; Oral; Participant; Patients; Pharmacological Treatment; Pharmacology; Physiology; Positron-Emission Tomography; Protocols documentation; Proxy; Public Health; Records; Recruitment Activity; Research; Research Methodology; Research Personnel; Retina; Retinal; Rewards; Secure; Severities; Signal Transduction; Smoker; Substance Use Disorder; Symptoms; Techniques; Testing; Tobacco; Tobacco Use Disorder; Tobacco smoking; Tobacco use; Training Programs; Variant; Ventral Striatum; Withholding Treatment; Writing; addiction; analytical method; base; biomarker development; career; cigarette smoking; cocaine use; contingency management; cost effectiveness; financial incentive; global health; individual patient; neuromechanism; neurotransmission; non-smoking; outcome prediction; predictive of treatment response; programs; psychostimulant; response; smoking cessation; treatment response

Project Title: Electroretinogram: A New Human Biomarker for Smoking Cessation Treatment Project Summary: In this application for a K23 Mentored Patient Oriented Research Career Development Award, Dr. Sean Luo proposes a comprehensive plan for developing into an independent researcher to develop biomarkers in substance use disorders, and in particular, tobacco use disorder. Specifically, this proposal will focus on developing a new human biomarker, electroretinogram, for dopamine release. Tobacco smoking continues to be a major public health challenge. Several lines of evidence suggest that dopamine release deficit is involved in the development and maintenance of nicotine dependence. We hypothesize that those smokers who do not have a deficit in dopamine release will more likely respond to behavioral treatments for smoking cessation, and in particular, financial incentives contingent on abstinence (Contingency Management). Previous pilot data suggest that flash blue cone electroretinogram (ERG), which records electrical signals from the retina in response to light, is a clinically accessible correlate to dopamine release in the brain. We propose an ERG-based biomarker, and a pilot clinical trial to apply this biomarker to personalize smoking cessation treatment. This clinically tractable biomarker of central dopamine release may have a large number of future applications in the diagnosis and treatment of other mental illnesses and substance use disorders. While pursuing this line of research with the expertise of his mentors (Dr. Edward Nunes and Dr. Frances Levin) and preceptors (Drs. Diana Martinez, Stephen Tsang, Alan Budney and Jill Williams), Dr. Luo will concurrently engage in an individualized training program so as to develop in the following important areas: (1) retinal physiology and biomarker development (2) retinal data analytic methods (3) clinical research methods (4) behavioral and pharmacological treatment of tobacco use disorder (5) grant writing and administration.

项目名称：视网膜电图：戒烟治疗的新人类生物标志物 项目摘要：在此申请 K23 指导的以患者为导向的研究职业发展 获奖后，罗肖恩博士提出了发展成为独立研究员的全面计划 开发物质使用障碍，特别是烟草使用障碍的生物标志物。具体来说，这 该提案将重点开发一种新的人类生物标志物，即视网膜电图，用于多巴胺的释放。烟草 吸烟仍然是一个重大的公共卫生挑战。多项证据表明多巴胺 释放不足与尼古丁依赖的形成和维持有关。我们假设 那些多巴胺释放不存在缺陷的吸烟者更有可能对行为治疗产生反应 戒烟，特别是根据戒烟情况提供的经济激励（应急措施 管理）。之前的试点数据表明，闪光蓝色锥体视网膜电图 (ERG) 记录了 视网膜响应光发出的电信号在临床上与多巴胺释放相关 大脑。我们提出了一种基于 ERG 的生物标志物，以及一项试点临床试验，以应用该生物标志物来个性化 戒烟治疗。这种临床上易于处理的中枢多巴胺释放生物标志物可能具有很大的作用。 未来在诊断和治疗其他精神疾病和药物滥用方面的应用数量 失调。在他的导师（Edward Nunes 博士和 Dr. Frances Levin）和导师（Diana Martinez 博士、Stephen Tsang、Alan Budney 和 Jill Williams）、罗博士 同时将开展个性化培训计划，以便在以下重要领域得到发展： (1) 视网膜生理学和生物标志物开发 (2) 视网膜数据分析方法 (3) 临床研究 方法 (4) 烟草使用障碍的行为和药物治疗 (5) 拨款写作和 行政。